Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
17.93
-0.95 (-5.05%)
At close: Jul 15, 2025
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $542.71M USD in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $545.21M, up 1,436.97% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$545.21M
Revenue Growth
+1,436.97%
P/S Ratio
4.31
Revenue / Employee
$895.25K
Employees
609
Market Cap
1.82B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Arrowhead Pharmaceuticals News
- 8 days ago - Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
- 23 days ago - Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire
- 6 weeks ago - Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
- 6 weeks ago - Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
- 6 weeks ago - Lightning Round: Buy Dover right now, says Jim Cramer - CNBC
- 6 weeks ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Business Wire
- 6 weeks ago - SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
- 6 weeks ago - Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) - Seeking Alpha